K. Colson

发表

Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib

K. Anderson, J. Laubach, P. Richardson, 2020, EJHaem.

K. Colson, Kathleen Colson, 2015, Supportive Care in Cancer.

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

Linda Z Sun, K. Anderson, C. Mitsiades, 2008, Leukemia & lymphoma.

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2007 .

Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.

K. Anderson, A. Jakubowiak, A. Krishnan, 2007 .

Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.

K. Colson, M. Gavino, K. Lilleby, 2008, Clinical journal of oncology nursing.

Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.

J. Tariman, R. Swift, K. Colson, 2004, Clinical journal of oncology nursing.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).

K. Anderson, A. Jakubowiak, A. Krishnan, 2006 .

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.

N. Munshi, J. Laubach, P. Richardson, 2010, Oncology.

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma

J. Laubach, P. Richardson, C. Mitsiades, 2021, Blood Cancer Journal.

Adherence, Persistence, and Treatment Fatigue in Multiple Myeloma

Joseph D Tariman, J. Tariman, S. Kurtin, 2016 .

Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma.

K. Noonan, K. Colson, Kimberly Noonan, 2017, Seminars in oncology nursing.

The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib

J. Laubach, P. Richardson, C. Mitsiades, 2012, European journal of haematology.

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.

A. Jakubowiak, A. Krishnan, S. Lonial, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.

Joseph D Tariman, J. Tariman, K. Miller, 2011, Clinical journal of oncology nursing.

Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis

N. Munshi, J. Laubach, P. Richardson, 2010 .

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010 .

Evidence-based recommendations for the management of symptoms and care for patients with multiple myeloma

Tracy Holloway King, J. Tariman, B. Faiman, 2020 .

Renal, GI, and Peripheral Nerves: Evidence‐based recommendations for the management of symptoms and care for patients with multiple myeloma

J. Tariman, B. Faiman, K. Colson, 2017 .

Renal, GI, and Peripheral Nerves: Evidence‐based recommendations for the management of symptoms and care for patients with multiple myeloma

Joseph D Tariman, J. Tariman, B. Faiman, 2017, Clinical journal of oncology nursing.

A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma.

S. Jagannath, N. Munshi, P. Richardson, 2005 .

Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.

Linda Z Sun, D. Siegel, P. Richardson, 2007 .

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib

A. Jakubowiak, A. Krishnan, S. Lonial, 2008 .

Expanding Role of Bortezomib in Multiple Myeloma: Nursing Implications

Joseph D Tariman, J. Tariman, R. Swift, 2008, Cancer nursing.

Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life

A. Hui, J. Laubach, P. Swinburn, 2015, Supportive Care in Cancer.

Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board.

Lisa C. Smith, J. Tariman, K. Miller, 2008, Clinical journal of oncology nursing.

Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).

N. Munshi, P. Richardson, N. Mitsiades, 2004 .

Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).

D. Esseltine, P. Wen, S. Lonial, 2004 .

Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.

S. Jagannath, P. Richardson, K. Colson, 2006, Clinical advances in hematology & oncology : H&O.

Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.

Joseph D Tariman, R. Swift, K. Colson, 2004 .

A Focus on Special Populations in Relapsed Multiple Myeloma

B. Faiman, K. Colson, M. Steinbach, 2022, Journal of the advanced practitioner in oncology.

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

A. Jakubowiak, S. Lonial, Jeffrey N. Martin, 2007 .